Cancer care in Sweden
The quality of cancer care in Sweden is high and survival rates for many types of cancer are above the European average. Although the economic and social impact of cancer on society is lower than the European average, Sweden spends more than an average European country on cancer treatment relative to its incidence. Cancer therefore continues to represent a substantial economic and social cost.
All.Can Sweden initiative
Sweden’s All.can initiative is a project sponsored by Bristol-Myers Squibb, Roche, Amgen, Janssen, Merck Sharp & Dohme and Microsoft.
The aim of the intiative is to improve cancer care and to create sustainable and equal conditions for the care of all cancer patients in Sweden. The initiative aims at developing proposals for improvements in Swedish cancer care, in dialogue with patient organisations, healthcare representatives, researchers, politicians and representatives from the health technology sector. The initiative strives to improve cancer prevention, diagnosis and treatment, as well as rehabilitation. A previous effort of All.Can in Sweden resulted in the Report “Swedish National Cancer Plan 2020 – improved access and reduced mortality
All.Can Sweden calls for national IT standards and better coordination of care
All.Can Sweden has published a policy report calling for national IT standards and improved coordination.
Swedish All.Can initiative launched
The All.Can initiative was officially launched in Sweden with the announcement of the Cancer Commission.
All.Can Sweden policy report
All.Can Sweden launched its policy report in June 2018. National Cancer Plan 2020: Improved access and reduced mortality – it is time to escalate the fight against cancer! is available in Swedish, with a summary version available in English.
- Download the full report in Swedish
- Download the summary report in English
Disclaimer:
The All.Can initiative is made up of leading representatives of patient organisations, policymakers, healthcare professionals, science and industry. All the publications produced as part of this initiative reflect a consensus of All.Can members, who retain full editorial control.
The All.Can initiative in Sweden is sponsored by Bristol-Myers Squibb, Roche, Amgen, Janssen, Merck Sharp & Dohme and Microsoft Sweden. None of the content developed from All.Can discussions and activities contains direct or indirect references to specific medicinal products or therapies.
All.Can is a trademark of The Health Policy Partnership Ltd.